Researchers are evaluating whether patients with metastatic NSCLC will benefit from stereotactic body radiation and a virally mediated gene therapy prior to nivolumab.
For this open-label phase 2 study, researchers are evaluating the safety and efficacy of nivolumab and ipilimumab among patients with 1 of these 3 cancer types.
Researchers are evaluating the feasibility and safety of adjuvant HIPEC in patients with locally advanced gastric cancer.
Data from previous studies suggest that adjuvant chemotherapy and PORT may improve patient outcomes, but the optimal sequence of administration was previously unestablished.
Researchers are evaluating whether Ad5-yCD/mutTKSR39rep-ADP, an oncolytic adenovirus, can help to improve outcomes among patients with inoperable stage I/IIA NSCLC.
A cumulative-use analysis suggests that NSAIDs, ACEis, and SSRIs improve disease-specific outcomes among patients with kidney cancer, and further that NSAIDs improve overall survival.
The most frequently reported adverse events associated with caplacizumab were epistaxis, gingival bleeding, and bruising.
Nearly 13% of patients in the edoxaban had first recurrent VTE or other major bleeding events during the 12-month follow-up compared with 13.5% of patients in the dalteparin arm.
Young patients with chronic ITP may experience relapse within 5 years of completing therapy.
Patients over the age of 65 years are the most frequently diagnosed group with hematologic cancers, yet these patients are typically under-enrolled in clinical studies evaluating novel therapies.
Researchers investigated whether PET-CT SUV has clinical utility among patients with CLL receiving venetoclax who failed therapy with ibrutinib or idelalisib.
Researchers randomly assigned 389 patients with R/R CLL to VR or BR study arms. Patients were stratified by del(17p) status, responsiveness to previous therapy, and geographic region.
Ongoing clinical trials should clarify optimal axilla management and treatment de-escalation options for patients with normal axillary ultrasound findings after neoadjuvant chemotherapy.
The phase 3 study ASPIRE previously demonstrated that adding carfilzomib to Rd prolongs progression-free survival, though overall survival data were immature.
A relevant prognostic factor for patients with MM is cytogenetic abnormalities, but the effect these abnormalities may have among high-risk transplant-ineligible patients treated with first-line bortezomib or lenalidomide had not previously been investigated.
Among the 60 evaluable patients, the objective response rate was 83%, with CR rate of 62%.
Researchers randomly assigned 1334 patients with untreated stage III or IV HL to receive A + AVD or ABVD for 6 cycles.
This analysis was undertaken to determine whether patient and disease characteristics can predict which patients will benefit from abemaciclib.
The CTS5 model is based on nodal status, tumor size, 3 categories of tumor grade, and age as a continuous variable.
Patients who presented with an MRD level below 10-6 had a significantly improved PFS compared with patients who were above this threshold.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Axillary Node Management for Breast Cancer: Is Less More?
- Non-steroidal Anti-inflammatory Drugs May Improve Survival in Kidney Cancer
- Potentially Inappropriate Medications May Shorten Survival Among Elderly Patients With Lymphoma
- Carfilzomib, Lenalidomide, Dexamethasone Prolong Survival in Multiple Myeloma
- The Potential of Radium-223 in Modern Prostate Cancer Treatment
- Colorectal Cancer Screening: Utility of Septin-9 Assays
- Phase 2 Trial of SBRT and Gene Therapy Prior to Nivolumab for NSCLC
- Phase 2 Study of Nivolumab Plus Ipilimumab for Gastric, Ovarian, and Breast Cancer
- Phase 1 Study of Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer
- Priming Lung Cancer To Respond to Immunotherapy: Findings and Current Research